Nrf2, a novel molecular target to reduce type 1 diabetes associated secondary complications: The basic considerations.

Antioxidant response element Diabetes Kelch-like ECH-associated protein 1 NADPH quinone dehydrogenase 1 Nuclear factor erythroid 2 (NFE2)-related factor 2 Reactive oxygen species

Journal

European journal of pharmacology
ISSN: 1879-0712
Titre abrégé: Eur J Pharmacol
Pays: Netherlands
ID NLM: 1254354

Informations de publication

Date de publication:
15 Jan 2019
Historique:
received: 30 01 2018
revised: 10 10 2018
accepted: 17 10 2018
pubmed: 26 10 2018
medline: 16 4 2019
entrez: 26 10 2018
Statut: ppublish

Résumé

Oxidative stress and inflammation are the mediators of diabetes and related secondary complications. Oxidative stress arises because of the excessive production of reactive oxygen species and diminished antioxidant production due to impaired Nrf2 activation, the master regulator of endogenous antioxidant. It has been established from various animal models that the transcription factor Nrf2 provides cytoprotection, ameliorates oxidative stress, inflammation and delays the progression of diabetes and its associated complications. Whereas, deletion of the transcription factor Nrf2 amplifies tissue level pathogenic alterations. In addition, Nrf2 also regulates the expression of numerous cellular defensive genes and protects against oxidative stress-mediated injuries in diabetes. The present review provides an overview on the role of Nrf2 in type 1 diabetes and explores if it could be a potential target for the treatment of diabetes and related complications. Further, the rationality of different agent's intervention has been discussed to mitigate organ damages induced by diabetes.

Identifiants

pubmed: 30359563
pii: S0014-2999(18)30611-3
doi: 10.1016/j.ejphar.2018.10.026
pii:
doi:

Substances chimiques

NF-E2-Related Factor 2 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

12-26

Informations de copyright

Copyright © 2018. Published by Elsevier B.V.

Auteurs

Chander K Negi (CK)

Facility for Risk Assessment and Intervention Studies, Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, Sector-67, S.A.S. Nagar, Punjab 160062, India.

Gopabandhu Jena (G)

Facility for Risk Assessment and Intervention Studies, Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, Sector-67, S.A.S. Nagar, Punjab 160062, India. Electronic address: gbjena@niper.ac.in.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH